Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (701-710 of 869) with videos related to

Pageof 87
Sort By:
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Molecular Cancer Therapeutics|April 5, 2012
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screeningRichard J Rickles, Winnie F Tam, Thomas P Giordano, et al.
Blood Advances|October 10, 2019
The impact of response kinetics for multiple myeloma in the era of novel agentsYuting Yan, Xuehan Mao, Jiahui Liu, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Leukemia|October 14, 2018
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cellsKrista Kinneer, Matt Flynn, Suneetha B Thomas, et al.
Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
Nature Medicine|February 25, 2026
Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancersFrancesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Blood|September 14, 2014
Pyk2 promotes tumor progression in multiple myelomaYu Zhang, Michele Moschetta, Daisy Huynh, et al.
Pageof 87

Showing results (701-710 of 869) with videos related to

Sort By:
Pageof 87
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Molecular Cancer Therapeutics|April 5, 2012
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screeningRichard J Rickles, Winnie F Tam, Thomas P Giordano, et al.
Blood Advances|October 10, 2019
The impact of response kinetics for multiple myeloma in the era of novel agentsYuting Yan, Xuehan Mao, Jiahui Liu, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Leukemia|October 14, 2018
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cellsKrista Kinneer, Matt Flynn, Suneetha B Thomas, et al.
Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
Nature Medicine|February 25, 2026
Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancersFrancesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Blood|September 14, 2014
Pyk2 promotes tumor progression in multiple myelomaYu Zhang, Michele Moschetta, Daisy Huynh, et al.
Pageof 87